National and Kapodistrian University of Athens
Επίδραση της αντικαταθλιπτικής αγωγής στη λειτουργική κατάσταση, την ποιότητα ζωής και βιοχημικούς και ηχωκαρδιογραφικούς δείκτες σε ασθενείς με χρόνια καρδιακή ανεπάρκεια και κατάθλιψη
Abstract
dc:descriptionBackground: Depression is a common comorbid condition in chronic heart failure (CHF) patients. Various pathopyshiologic mechanisms have been proposed that link these two syndromes. The effect of antidepressive treatment in CHF patients with depression has not been extensively studied.Objective / Aim: This study investigates the plasma levels of markers of inflammation, oxidative stress markers and cell adhesion molecules in depressed CHF patients as well as the effects of antidepressant treatment with Sertraline on these markers in the same patient population. Population and Methods: Patients with positive depression screening [Beck Depression Inventory (BDI) score >10 and/or Zung Self rating Depression Scale (Zung SDS) >40] underwent a psychiatric interview. Patients newly diagnosed as depressed, received pharmacological treatment with Sertraline for three months (arm A) and were compared with those who did not comply with the antidepressant treatment (arm B). Markers of oxidative stress such as malondialdehyde (MDA) and protein carbonyls (PC), and nitrosative stress [nitrotyrosine (NT)] were also assessed at baseline and 3 months later. Also, cell adhesion molecules intracellular adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1) were assessed in a number of the study group patients. Results: Fifty-two out of 254 screened hospitalized CHF patients were diagnosed as depressed. Depressed patients had significantly higher levels of MDA compared to age- and gender-matched non-depressed patients (n=40) (3.2 ± 2.0 vs 2.8 ± 3.8 μmol/lt, p=0.02). Twenty-eight patients received Sertraline (arm A), while 24 refused to receive anti-depressant treatment on the top of optimal heart failure treatment (arm B). While baseline levels of MDA, PC and NT in arm A and arm B did not differ significantly (p>0.05), only arm A patients demonstrated a significant reduction on MDA (F=4.657, p=0.037), while arm B patients demonstrated no change after three months. Concerning the examined scores, arm A patients had a decrease in BDI score (23 ± 11 vs 19 ± 12, p=0.015), while arm B patients had no change in BDI score at follow-up (p>0.05). Arm A had an increase in 6-min walking distance (291 ± 110 vs 361 ± 87 meters, p=0.02), while arm B experienced no change in this parameter (p>0.05). Furthermore, in a subpopulation of 25 depressive patients, blood samples for measurement of cell adhesion molecules ICAM-1 and VCAM-1 were obtained and analyzed before and after SSRI administration (n= 13) or standard heart failure treatment alone (n=12). It was shown that Sertraline administration for 3 months was associated with a decrease of ICAM-1 and VCAM-1 serum levels in comparison to untreated patients (change in ICAM-1: -20% vs +23%, F=5.24 p=0.028, change in VCAM-1: -20% vs +17%, F=4.54 p=0.04). Conclusions: Increased oxidative stress may play a critical role in the pathophysiology of depression in CHF. Treatment with Sertraline improves depressive symptoms and reduces plasma markers of lipid peroxidation in depressed CHF patients. Furthermore, it exerts a beneficiary action on inflammation and endothelial function leading to a decrease in cell adhesion molecule expression and improvement in exercise capacity in treated patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Michalakeas, Christos
- Μιχαλακέας, Χρήστος
Subjects
dc:subject × 14- Κατάθλιψη
- Χρόνια καρδιακή ανεπάρκεια
- Οξειδωτικό στρες
- Φλεγμονή
- Εκλεκτικοί αναστολείς επαναπρόσληψης σεροτονίνης
- Depression
- Chronic cardiac failure
- Oxidative stress
- Inflammation
- Selective serotonin reuptake inhibitors
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42398